Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular S...
March 17 2021 - 8:33AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”,
“We”, “Our” or “Inotiv”), doing business as Inotiv, a
leading provider of nonclinical and analytical contract research
services, today announced plans to expand the Company’s service
offerings to add cardiovascular safety pharmacology capabilities to
the existing capabilities for respiratory and central nervous
system safety pharmacology.
Safety pharmacology evaluations are critical for assessing the
impact of drug candidates. By summer 2021, Inotiv expects to offer
integrated safety pharmacology packages that include core battery
tests for cardiovascular, respiratory, and central nervous system
functions as standalone safety pharmacology packages or as part of
a full investigational new drug / clinical trial application
program. The Company previously relied on subcontractors for these
cardiovascular assessments.
“Over the past year, we’ve made significant investments towards
reducing our subcontracted and outsourced work,” said Company
President and Chief Executive Officer Robert Leasure, Jr. “This is
a continuation of that strategy that we believe will allow us to
improve speed and control quality of services while also enhancing
margins.”
“The initiative to add cardiovascular safety pharmacology began
in April 2020, as we assembled our cardiovascular safety
pharmacology team and conducted validation studies to fully support
this new offering. This is yet another step we’re taking to support
our growth strategy and expand our current suite of services to
provide the broad scope and right-sized solutions crucial to the
success of our clients.”
About the CompanyBioanalytical Systems, Inc.,
doing business as Inotiv, is a pharmaceutical development company
providing contract research services and monitoring instruments to
emerging pharmaceutical companies and the world's leading drug
development companies and medical research organizations. The
Company focuses on developing innovative services supporting its
clients’ discovery and development objectives for improved
decision-making and accelerated goal attainment. The Company’s
products focus on increasing efficiency, improving data, and
reducing the cost of taking new drugs to market. Visit inotivco.com
for more information about the Company.
This release may contain forward-looking
statements that are subject to risks and uncertainties including,
but not limited to, risks and uncertainties related to changes in
the market and demand for our products and services, the
development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, the timing of
acquisitions and the successful closing, integration and business
and financial impact thereof, the impact of the COVID-19 pandemic
on the economy, demand for our services and products and our
operations, including the measures taken by governmental
authorities to address the pandemic, which may precipitate or
exacerbate other risks and/or uncertainties and various other
market and operating risks, including those detailed in the
Company's filings with the U.S. Securities and Exchange
Commission.
Company Contact |
Investor Relations |
Bioanalytical Systems, Inc., dba Inotiv |
The Equity Group Inc. |
Beth A. Taylor, Chief Financial Officer |
Kalle Ahl, CFA |
(765) 497-8381 |
(212) 836-9614 |
btaylor@inotivco.com |
kahl@equityny.com |
|
|
|
Devin Sullivan |
|
(212) 836-9608 |
|
dsullivan@equityny.com |
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024